The role of methadone in cancer pain treatment - a review
Tóm tắt
Từ khóa
Tài liệu tham khảo
World Health Organisation, 1996, Cancer Pain Relief and Palliative Care
Hanks, 2004, Oxford Textbook of Palliative Medicine, 316
Hanks, 2001, Morphine and alternative opioids in cancer pain: the EAPC recommendations, Br J Cancer, 84, 587, 10.1054/bjoc.2001.1680
Mercadante, 1999, Opioid rotation for cancer pain. Rationale and clinical aspects, Cancer, 86, 1856, 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G
Fishman, 2002, Methadone reincarnated: novel clinical applications with related concerns, Pain Med, 3, 339, 10.1046/j.1526-4637.2002.02047.x
Manfredi, 2003, Parenteral methadone: an essential medication for the treatment of pain, J Pain Symptom Manage, 26, 687, 10.1016/S0885-3924(03)00259-8
Mercadante, 2001, Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study, J Clin Oncol, 19, 2898, 10.1200/JCO.2001.19.11.2898
Mercadante, 2005, Rapid switching between transdermal fentanyl and methadone in cancer patients, J Clin Oncol, 23, 5229, 10.1200/JCO.2005.13.128
Mercadante, 2005, Hyperalgesia and opioid switching, Am J Hosp Palliat Med, 22, 291, 10.1177/104990910502200411
Zimmermann, 2005, Rotation to methadone after opioid dose escalation: how should individualization of dosing occur?, J Pain Palliat Care Pharmacother, 19, 25
De Stoutz, 1995, Opioid rotation for toxicity reduction in terminal cancer patients, J Pain Symptom Manage, 10, 378, 10.1016/0885-3924(95)90924-C
Ripamonti, 2001, Strategies for the treatment of cancer pain in the new millenium, Drugs, 61, 955, 10.2165/00003495-200161070-00005
Moryl, 2005, Methadone in the treatment of pain and terminal delirium in advanced cancer patients, Palliat Support Care, 3, 311, 10.1017/S1478951505050479
Mancini, 2000, Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study, J Palliat Med, 3, 49, 10.1089/jpm.2000.3.49
Daeninck, 1999, Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases, J Pain Symptom Manage, 18, 303, 10.1016/S0885-3924(99)00086-X
Mancini, 2000, Opioid switch to oral methadone in cancer pain, Curr Opin Oncol, 12, 308, 10.1097/00001622-200007000-00006
Scholes, 1999, Methadone titration in opioid-resistant cancer pain, Eur J Cancer Care, 8, 26, 10.1046/j.1365-2354.1999.00133.x
Gannon, 1997, The use of methadone in the care of dying, Eur J Palliat Care, 4, 152
Twycross, 1998, Nausea and vomiting in advanced cancer, Eur J Palliat Care, 5, 39
De Conno, 1996, Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients, J Clin Oncol, 14, 2836, 10.1200/JCO.1996.14.10.2836
Bruera, 2004, Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study, J Clin Oncol, 22, 185, 10.1200/JCO.2004.03.172
Ventafridda, 1986, A randomized study on oral administration of morphine and methadone in the treatment of cancer pain, J Pain Symptom Manage, 1, 203, 10.1016/S0885-3924(86)80042-2
Twycross, 2001, Symptom Management in Advanced Cancer, 17
Shir, 1998, Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases, Clin J Pain, 14, 350, 10.1097/00002508-199812000-00013
Davies, 2008, Methadone analgesia for children with advanced cancer, Pediatr Blood Cancer, 51, 393, 10.1002/pbc.21584
Mercadante, 2001, Methadone in treatment of tenesmus not responsive to morphine escalation, Support Care Cancer, 9, 129, 10.1007/s005200000207
Mannino, 2006, Methadone for cancer-related neuropathic pain: a review of the literature, J Opioid Manag, 2, 269, 10.5055/jom.2006.0040
Davis, 2001, Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration, Support Care Cancer, 9, 73, 10.1007/s005200000180
Maneckjee, 1994, Opioids induce while nicotine suppresses apoptosis in human lung cancer cells, Cell Growth Differ, 5, 1033
Tubaro, 1985, Morphine and methadone impact on human phagocytic physiology, Int J Immunopharmacol, 7, 865, 10.1016/0192-0561(85)90049-9
Fainsinger, 1993, Methadone in the management of cancer pain: a review, Pain, 52, 137, 10.1016/0304-3959(93)90125-9
Gorman, 1997, The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord, Neurosci Lett, 223, 5, 10.1016/S0304-3940(97)13391-2
Ebert, 1995, Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord, Neurosci Lett, 187, 165, 10.1016/0304-3940(95)11364-3
Codd, 1995, Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception, J Pharmacol Exp Ther, 274, 1263
Bulka, 2002, Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy, Pain, 95, 103, 10.1016/S0304-3959(01)00382-7
Crews, 1993, Clinical efficacy of methadone in patients refractory to other μ-opioid receptor agonist analgesics for management of terminal cancer pain, Cancer, 72, 2266, 10.1002/1097-0142(19931001)72:7<2266::AID-CNCR2820720734>3.0.CO;2-P
Galer, 1992, Individual variability in the response to different opioids: report of five cases, Pain, 49, 87, 10.1016/0304-3959(92)90192-E
Mercadante, 1998, Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home, J Clin Oncol, 16, 3656, 10.1200/JCO.1998.16.11.3656
Säwe, 1986, High-dose morphine and methadone in cancer patients, clinical pharmacokinetic considerations of oral treatment, Clin Pharmacokin, 11, 87, 10.2165/00003088-198611020-00001
Ferrari, 2004, Methadone - metabolism, pharmacokinetics and interactions, Pharmacol Res, 50, 551, 10.1016/j.phrs.2004.05.002
Gourlay, 1986, A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, 25, 297, 10.1016/0304-3959(86)90234-4
Ripamonti, 1997, An update on the clinical use of methadone in cancer pain, Pain, 70, 109, 10.1016/S0304-3959(96)03286-1
Verebely, 1975, Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment, Clin Pharmacol Ther, 18, 180, 10.1002/cpt1975182180
Oda, 2001, Metabolism of methadone and levo-α-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearence and bioactivation, J Pharmacol Exp Ther, 298, 1021
Kharasch, 2004, Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone, Clin Pharmacol Ther, 76, 250, 10.1016/j.clpt.2004.05.003
Dean, 2004, Opioids in renal failure and dialysis patient, J Pain Symptom Manage, 28, 497, 10.1016/j.jpainsymman.2004.02.021
Ripamonti, 2002, The use of methadone for cancer pain, Hematol Oncol Clin North Am, 16, 543, 10.1016/S0889-8588(02)00017-5
Weschules, 2008, Actual and potential drug interactions associated with methadone, Pain Med, 9, 315, 10.1111/j.1526-4637.2006.00289.x
Crettol, 2005, Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment, Clin Pharmacol Ther, 78, 593, 10.1016/j.clpt.2005.08.011
Haddad, 2007, The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions, Support Care Cancer, 15, 251, 10.1007/s00520-006-0127-5
Ferrer-Brechner, 1984, Combination therapy with ibuprofen and methadone for chronic cancer pain, Am J Med, 77, 78, 10.1016/S0002-9343(84)80023-6
Mercadante, 1997, Opioid-sparing effect of diclofenac in cancer pain, J Pain Symptom Manage, 14, 15, 10.1016/S0885-3924(97)00005-5
Cichewicz, 1999, Enhancement of μ opioid antinociception by oral Δ9-tetrahydrocannabinol: dose-response analysis and receptor identification, J Pharmacol Exp Ther, 289, 859
Abramson, 1982, Methadone plasma protein binding: alterations in cancer and displacement from alpha-1-acid glicoprotein, Clin Pharmacol Ther, 32, 652, 10.1038/clpt.1982.217
Kostka - Trabka, 2006, Interakcje Lekow w Praktyce Kliniczne, 13
Wu, 1993, Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone, Br J Clin Pharmacol, 35, 30, 10.1111/j.1365-2125.1993.tb05666.x
Bruera, 2002, Methadone use in cancer patients with pain: a review, J Palliat Med, 5, 127, 10.1089/10966210252785097
Mercadante, 2006, Opioid switching: a systematic and critical review, Cancer Treat Rev, 32, 304, 10.1016/j.ctrv.2006.03.001
Mercadante, 1999, Rapid switching from morphine to methadone in cancer patients with poor response to morphine, J Clin Oncol, 17, 3307, 10.1200/JCO.1999.17.10.3307
Morley, 1998, The use of methadone in cancer pain poorly responsive to other opioids, Pain Rev, 5, 51, 10.1191/096813098673619329
Nauck, 2001, A German model for methadone conversion, Am J Hosp Palliat Care, 18, 200, 10.1177/104990910101800312
Ripamonti, 1998, Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?, J Clin Oncol, 16, 3216, 10.1200/JCO.1998.16.10.3216
Gagnon, 1999, Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain, J Pain Symptom Manage, 18, 120, 10.1016/S0885-3924(99)00049-4
Bruera, 2000, Proceedings of the 9th World Congress of Pain, Progress in Pain Research and Management, 957
Leppert, 2005, Rola metadonu w leczeniu bolu nowotworowego, Bol, 6, 9
Ayonrinde, 2000, The rediscovery of methadone for cancer pain management, Med J Aust, 173, 536, 10.5694/j.1326-5377.2000.tb139323.x
Soares, 2005, Methadone for cancer pain: what have we learned from clinical studies?, Am J Hosp Palliat Care, 22, 223, 10.1177/104990910502200312
Mercadante, 2003, Opioid plasma concentration during switching from morphine to methadone: preliminary data, Support Care Cancer, 11, 326, 10.1007/s00520-003-0440-1
Mercadante, 2004, Switching to methadone: ‘ad libitum’ or fixed dose ratio?, Palliat Med, 18, 71, 10.1191/0269216304pm860xx
Mercadante, 2007, Opioid plasma concentrations during a switch from transdermal fentanyl to methadone, J Palliat Med, 10, 338, 10.1089/jpm.2006.0140
Hagen, 1999, Methadone: outpatient titration and monitoring strategies in cancer patients, J Pain Symptom Manage, 18, 369, 10.1016/S0885-3924(99)00083-4
Pereira, 2001, Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing, J Pain Symptom Manage, 22, 672, 10.1016/S0885-3924(01)00294-9
Bruera, 1996, Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine, Cancer, 78, 852, 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T
Lawlor, 1998, Dose ratio between morphine and methadone in patients with cancer pain. A retrospective study, Cancer, 82, 1167, 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3
Ripamonti, 1998, Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences, Ann Oncol, 9, 79, 10.1023/A:1008263910494
Cornish, 2003, An alternative low-dose ad libitum schedule for conversion of other opioids to methadone, Palliat Med, 17, 643, 10.1191/0269216303pm820xx
Anderson, 2001, Accuracy in equianalgesic dosing: conversion dilemmas, J Pain Symptom Manage, 21, 397, 10.1016/S0885-3924(01)00271-8
Weschules, 2008, A systematic review of opioid conversion ratios used with methadone for the treatment of pain, Pain Med, 9, 595, 10.1111/j.1526-4637.2008.00461.x
Laird, 2005, Methadone titration: still no gauge on the tank, Palliat Med, 19, 568
Hernansanz, 2006, Opioid rotation to methadone at home, J Pain Symptom Manage, 31, 2, 10.1016/j.jpainsymman.2005.12.005
Moryl, 2002, Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain, Pain, 96, 325, 10.1016/S0304-3959(01)00465-1
Doverty, 2001, Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine, Pain, 93, 155, 10.1016/S0304-3959(01)00306-2
Walker, 2008, Switching from methadone to a different opioid: what is the equianalgesic dose ratio?, J Palliat Med, 11, 1103, 10.1089/jpm.2007.0285
Lugo, 2005, Pharmacokinetics of methadone, J Pain Palliat Care Pharmacother, 19, 13, 10.1080/J354v19n04_05
Berdine, 2006, Equianalgesic dosing of opioids, J Pain Palliat Care Pharmacother, 20, 79, 10.1080/J354v20n04_16
Leppert, 2005, The role of methadone in cancer pain treatment - Polish experience, Progr Palliat Care, 13, 269, 10.1179/096992605X75868
Blackburn, 2005, Methadone: the analgesic, Eur J Palliat Care, 12, 188
Fisher, 2004, Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study, J Pain Symptom Manage, 28, 619, 10.1016/j.jpainsymman.2004.03.003
Hagen, 2007, Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study, J Palliat Med, 10, 331, 10.1089/jpm.2006.0163
Zeppetella, 2008, Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief, J Pain Symptom Manage, 35, 563, 10.1016/j.jpainsymman.2007.06.012
Ripamonti, 1995, Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study, Ann Oncol, 6, 841, 10.1093/oxfordjournals.annonc.a059327
Bruera, 1995, Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain, Pain, 62, 141, 10.1016/0304-3959(94)00257-F
Watanabe, 1996, Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations, Cancer Treat Rev, 22, 131, 10.1016/S0305-7372(96)90075-4
Dale, 2004, Bioavailabilities of rectal and oral methadone in healthy subjects, Br J Clin Pharmacol, 58, 156, 10.1111/j.1365-2125.2004.02116.x
Makin, 2000, Subcutaneous methadone in terminally ill patients, J Pain Symptom Manage, 19, 237, 10.1016/S0885-3924(00)00111-1
Bruera, 1991, Local toxicity with subcutaneous methadone. Experience of two centers, Pain, 45, 141, 10.1016/0304-3959(91)90179-2
Hum, 2007, Subcutaneous methadone - an issue revisited, J Pain Symptom Manage, 34, 573, 10.1016/j.jpainsymman.2007.08.005
Mathew, 1999, Subcutaneous methadone in terminally ill patients: manageable local toxicity, J Pain Symptom Manage, 18, 49, 10.1016/S0885-3924(99)00020-2
Centeno, 2005, Intermittent subcutaneous methadone administration in the management of cancer pain, J Pain Palliat Care Pharmacother, 19, 7, 10.1080/J354v19n02_03
103Guidelines for the Use of Methadone in Cancer Pain. http://www.palliativedrugs.com/methadone.html (accessed November 2008).
Vielvoye-Kerkmeer, 2008, Re: subcutaneous methadone, an issue revisited, J Pain Symptom Manage, 35, 572, 10.1016/j.jpainsymman.2008.01.005
Grochow, 1989, Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study, Pain, 38, 151, 10.1016/0304-3959(89)90233-9
Fitzgibbon, 1997, Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine, Pain, 73, 259, 10.1016/S0304-3959(97)00118-8
Sabatowski, 2002, Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine, J Pain Symptom Manage, 23, 3, 10.1016/S0885-3924(01)00389-X
Santiago-Palma, 2001, Intravenous methadone in the management of chronic cancer pain. Safe and effective starting doses when substituting methadone for fentanyl, Cancer, 92, 1919, 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G
Manfredi, 1997, Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations, Pain, 70, 99, 10.1016/S0304-3959(96)03313-1
Gallagher, 2004, Methadone mouthwash for the management of oral ulcer pain, J Pain Symptom Manage, 27, 390, 10.1016/j.jpainsymman.2004.02.008
Gallagher, 2005, Analgesic effects of topical methadone: a report of four cases, Clin J Pain, 21, 190, 10.1097/00002508-200503000-00012
Hassenbusch, 2004, Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery - report of an expert panel, J Pain Symptom Manage, 27, 540, 10.1016/j.jpainsymman.2004.03.001
Shir, 2001, Methadone is safe for treating patients with severe pain, Can J Anesth, 48, 1109, 10.1007/BF03020377
Dale, 2002, Disposition of nasal, intravenous, and oral methadone in healthy volunteers, Clin Pharmacol Ther, 72, 536, 10.1067/mcp.2002.128386
Weinberg, 1988, Sublingual absorption of selected opioid analgesics, Clin Pharmacol Ther, 44, 335, 10.1038/clpt.1988.159
Nicholson, 2007, Methadone for cancer pain, Cochrane Database Syst Rev, 10.1002/14651858.CD003971.pub3
LoVecchio Do, 2007, Onset of symptoms after methadone overdose, Am J Emerg Med, 25, 57, 10.1016/j.ajem.2006.07.006
Mercadante, 2008, Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management, Eur J Pain, 12, 1040, 10.1016/j.ejpain.2008.01.013
Mercadante, 1999, Methadone response in advanced cancer patients with pain followed at home, J Pain Symptom Manage, 18, 188, 10.1016/S0885-3924(99)00048-2
Hansen, 1982, Clinical evaluation of oral methadone in treatment of cancer pain, Acta Anaesth Scand, 74, 124, 10.1111/j.1399-6576.1982.tb01860.x
Sarhill, 2001, Methadone-induced myoclonus in advanced cancer, Am J Hosp Palliat Med, 18, 51, 10.1177/104990910101800113
Ito, 2008, Myoclonus associated with high-dose parenteral methadone, J Palliat Med, 11, 838, 10.1089/jpm.2008.0040
Lussier, 2003, Choreiform movements after a single dose of methadone, J Pain Symptom Manage, 26, 688, 10.1016/S0885-3924(03)00256-2
Bush, 2006, A case of serotonin syndrome and mutism associated with methadone, J Palliat Med, 9, 1257, 10.1089/jpm.2006.9.1257
Mercadante, 2003, Hyperalgesia: an emerging iatrogenic syndrome, J Pain Symptom Manage, 26, 769, 10.1016/S0885-3924(03)00258-6
Walker, 2003, High dose methadone and ventricular arrhythmias: a report of three cases, Pain, 103, 321, 10.1016/S0304-3959(02)00461-X
Krantz, 2002, Torsade de pointes associated with very-high-dose-methadone, Ann Intern Med, 137, 501, 10.7326/0003-4819-137-6-200209170-00010
Kornick, 2003, QTc interval prolongation associated with intravenous methadone, Pain, 105, 499, 10.1016/S0304-3959(03)00205-7
Cruciani, 2005, Measurement of QTc in patients receiving chronic methadone therapy, J Pain Symptom Manage, 29, 385, 10.1016/j.jpainsymman.2004.06.012
Chugh, 2008, A community-based evaluation of sudden death associated with therapeutic levels of methadone, Am J Med, 121, 66, 10.1016/j.amjmed.2007.10.009
Manfredi, 2003, Prescribing methadone, a unique analgesic, J Support Oncol, 1, 216
Sekine, 2007, The successful use of parenteral methadone in a patient with a prolonged QTc interval, J Pain Symptom Manage, 34, 566, 10.1016/j.jpainsymman.2007.05.001
Ower, 2005, Fluctuating QTc interval in an asymptomatic patient treated with methadone for chronic pain, J Opioid Manage, 1, 73, 10.5055/jom.2005.0019
Cruciani, 2008, Methadone: to ECG or not to ECG…that is still the question, J Pain Symptom Manage, 36, 545, 10.1016/j.jpainsymman.2007.11.003
Oneschuk, 2000, Respiratory depression during methadone rotation in a patient with advanced cancer, J Palliat Care, 16, 50, 10.1177/082585970001600209
Hunt, 1995, Respiratory depression in a patient receiving oral methadone for cancer pain, J Pain Symptom Manage, 10, 401, 10.1016/0885-3924(95)00021-P
Tarumi, 2002, Methadone and fluconazole: respiratory depression by drug interaction, J Pain Symptom Manage, 23, 148, 10.1016/S0885-3924(01)00368-2
Benitez-Rosario, 2006, Methadone-induced respiratory depression after discontinuing carbamazepine administration, J Pain Symptom Manage, 32, 99, 10.1016/j.jpainsymman.2006.02.006
Leppert, 2008, The role of methadone in opioid rotation - a Polish experience, Support Care Cancer
Mercadante, 1996, Patient-controlled analgesia with oral methadone in cancer pain: preliminary report, Ann Oncol, 7, 613, 10.1093/oxfordjournals.annonc.a010679
Tse, 2003, An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population, Palliat Med, 17, 206, 10.1191/0269216303pm696oa
Säwe, 1981, Patient-controlled dose regimen of methadone for chronic cancer pain, BMJ, 282, 771, 10.1136/bmj.282.6266.771
Quigley, 2004, Opioid switching to improve pain relief and drug tolerability, Cochrane Database Syst Rev, 10.1002/14651858.CD004847
Fredheim, 2008, Clinical pharmacology of methadone for pain, Acta Aanaesth Scand, 252, 879, 10.1111/j.1399-6576.2008.01597.x
Donnelly, 2002, Morphine in cancer pain management: a practical guide, Support Care Cancer, 10, 13, 10.1007/s005200100274
Sarhill, 2001, Hydromorphone: pharmacology and clinical applications in cancer patients, Support Care Cancer, 9, 84, 10.1007/s005200000183
Riley, 2008, Oxycodone: a review of its use in the management of pain, Curr Med Res Opin, 24, 175, 10.1185/030079908X253708
Mercadante, 2007, Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients, Support Care Cancer, 15, 441, 10.1007/s00520-006-0169-8